清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Updated Results from a Phase 1b study of olverembatinib (HQP1351) combined with lisaftoclax (APG-2575) in pediatric patients with relapsed/refractory Philadelphia Chromosome–Positive acute lymphoblastic leukemia

医学 内科学 队列 急性淋巴细胞白血病 微小残留病 淋巴细胞白血病 不利影响 地塞米松 临床终点 药代动力学 临床研究阶段 儿科 临床试验 养生 加药 化疗 队列研究 白血病 百时美 化疗方案 外科 急性胸部综合征 肿瘤科 小儿癌症 前瞻性队列研究
作者
Jingliao Zhang,Junxia Wang,Huanshan Guo,Tianfeng Liu,Yingchi Zhang,Zi Chen,Wenyu Yang,Hengbang Wang,Yifan Zhai,Xiaofan Zhu
出处
期刊:Blood [Elsevier BV]
卷期号:146 (Supplement 1): 6876-6876
标识
DOI:10.1182/blood-2025-6876
摘要

Abstract Background Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) in pediatric patients remains a high-risk subtype with limited treatment options after tyrosine kinase inhibitor (TKI) failure. Olverembatinib is a potent third-generation TKI with activity against BCR::ABL1 genetic variants, including T315I. Lisaftoclax, a selective BCL-2 inhibitor, has shown encouraging activity in hematologic malignancies. This ongoing phase 1b study evaluates the safety, tolerability, preliminary efficacy, and pharmacokinetics of olverembatinib combined with lisaftoclax in pediatric patients with relapsed/refractory (R/R) Ph+ ALL. Methods This open-label, dose-escalation and expansion study (NCT05495035) enrolled pediatric patients aged <18 years with R/R Ph+ALL resistant or intolerant to ≥ 1 prior TKI. Patients received olverembatinib monotherapy (40 mg adult-equivalent dose [AED], every other day, days 1–14), followed by combination therapy with lisaftoclax (200, 400, or 600 mg AED daily, with 3-day dose ramp-up) and dexamethasone (6 mg/m²/day, days 15–42). Primary endpoints included safety, overall response rate (ORR), measurable residual disease (MRD) negativity, and pharmacokinetics. A dose-expansion cohort was initiated with lisaftoclax 600 mg AED combined with olverembatinib 40 mg AED. Results As of the data cutoff date of June 26, 2025, 15 patients(median age 13.0 years, range 9–15) were enrolled. All had R/R Ph+ ALL; 33.3% (5/15) harbored BCR::ABL1 genetic variants, including baseline T315I (n = 4) and F317L (c.951C>A) (n = 1). Median body weight was 44.3 kg (range 22.8–86.0). Fourteen patients (93.3%) had the p190 transcript and one (6.7%) had the p210 transcript. One patient discontinued on cycle 1 day 1 (C1D1) because of a seizure. Fourteen eligible patients (8/14, R/R; 5/14, intolerant, 1 both R/R and intolerant) received lisaftoclax at AEDs of 200 (n = 3), 400 (n = 3), or 600 mg (n = 8). These patients completed two treatment cycles and were assessed for the primary endpoints. Twelve of 15 patients (80%) experienced grade ≥ 3 hematologic treatment-emergent adverse events (TEAEs), including neutropenia (46.7%, n = 7), anemia (26.7%, n = 4), thrombocytopenia (20.0%, n = 3), and elevated hepatic transaminases (6.7%, n = 1). Two patients (13.3%) discontinued because of adverse events (one seizure on C1D1, one hepatic toxicity). Among 8 patients evaluable for morphologic response, the ORR (complete remission [CR] + CR with incomplete count recovery [CRi]) improved substantially from prior analysis. At the end of olverembatinib monotherapy (EOM), the ORR was 50% (4/8; 2 CR, 2 CRi). By C2D15 (mid-cycle) and end of combination therapy (EOC; C2D27), the ORR increased to 87.5% (7/8; all CR). These response rates represent marked improvements from the interim analysis (ORR, 33.3% [2/6] at EOM, 83.3% [5/6] at EOC). Among 11 evaluable patients, MRD negativity was observed in 7 (63.6%) by C2D15 and C2D27. MRD-negative responses occurred across all dose levels, including in patients with baseline BCR::ABL1 genetic variants. Pharmacokinetic data demonstrated comparable exposure to adult profiles for both agents, with no significant drug accumulation or drug-drug interactions, supporting the feasibility of this regimen in pediatric patients. Conclusions This updated analysis further supports the safety, tolerability, and promising antileukemic activity of olverembatinib combined with lisaftoclax in pediatric patients with R/R Ph+ ALL. The regimen demonstrated rapid and deep remissions with high MRD negativity rates and favorable pharmacokinetics. Importantly, these outcomes were achieved without intensive chemotherapy or immunotherapy, highlighting this novel combination as an effective orally active and chemotherapy-free treatment option for this high-risk pediatric population. The study is ongoing for further efficacy and safety assessments and regimen optimization.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
深情豁完成签到,获得积分10
2秒前
科研通AI6.4的应助被DongQiu1993采纳,获得10
5秒前
激情的汲完成签到,获得积分10
9秒前
考拉完成签到 ,获得积分10
11秒前
醉熏的小凡完成签到,获得积分10
27秒前
迷路的含桃完成签到 ,获得积分10
29秒前
宁赴湘完成签到 ,获得积分10
32秒前
包容大地完成签到,获得积分10
38秒前
小田完成签到 ,获得积分10
39秒前
46秒前
科研小将发布了新的文献求助10
50秒前
Xzx1995完成签到 ,获得积分10
55秒前
qvb完成签到 ,获得积分10
57秒前
我来也完成签到 ,获得积分10
59秒前
默默问芙完成签到,获得积分10
1分钟前
SZ完成签到 ,获得积分10
1分钟前
从容棉花糖完成签到,获得积分10
1分钟前
CC完成签到,获得积分10
1分钟前
打打的应助被科研小将采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
愤怒的微笑完成签到,获得积分10
1分钟前
wwwwwl完成签到 ,获得积分10
1分钟前
典雅的醉易完成签到,获得积分10
1分钟前
新人钱粮完成签到 ,获得积分10
1分钟前
1分钟前
my完成签到 ,获得积分10
1分钟前
华仔的应助被冥土追魂采纳,获得10
1分钟前
leng发布了新的文献求助10
1分钟前
Tonald Yang完成签到,获得积分20
1分钟前
xiami完成签到,获得积分10
1分钟前
Arctic完成签到 ,获得积分10
1分钟前
能干的新筠完成签到,获得积分10
1分钟前
跳跃的凡阳完成签到,获得积分10
1分钟前
suifeng91完成签到,获得积分10
2分钟前
超帅的香露完成签到,获得积分10
2分钟前
molihuakai的应助被俏皮诺言采纳,获得10
2分钟前
Yi完成签到,获得积分0
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166463
求助须知:如何正确求助?哪些是违规求助? 9559520
关于积分的说明 21750530
捐赠科研通 7757265
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553511
邀请新用户注册赠送积分活动 2473845